Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.45 USD | -0.31% | -3.63% | +22.51% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 861.3 | 161.7 | 331.8 | 413 | - | - |
Enterprise Value (EV) 1 | 1,175 | 547.9 | 331.8 | 741 | 689 | 630.8 |
P/E ratio | 34 x | -1.01 x | -2.12 x | -80.2 x | 89 x | 11.7 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 2 x | 0.32 x | 0.65 x | 0.76 x | 0.72 x | 0.69 x |
EV / Revenue | 2.73 x | 1.07 x | 0.65 x | 1.36 x | 1.2 x | 1.06 x |
EV / EBITDA | 14.5 x | 8.26 x | 3.73 x | 7.68 x | 6.63 x | 5.73 x |
EV / FCF | 75.2 x | -23.2 x | - | 16.6 x | 11.9 x | 8.09 x |
FCF Yield | 1.33% | -4.3% | - | 6.01% | 8.43% | 12.4% |
Price to Book | 2.38 x | 0.64 x | - | 1.87 x | 1.73 x | 1.55 x |
Nbr of stocks (in thousands) | 59,438 | 61,952 | 62,966 | 63,828 | - | - |
Reference price 2 | 14.49 | 2.610 | 5.270 | 6.470 | 6.470 | 6.470 |
Announcement Date | 3/10/22 | 3/31/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 340.1 | 321.2 | 430.9 | 512.1 | 512.3 | 543 | 574.5 | 594.4 |
EBITDA 1 | - | 72.44 | 80.76 | 66.31 | 88.86 | 96.44 | 103.9 | 110 |
EBIT 1 | 31.19 | 58.61 | 85.36 | 47.95 | 81.05 | 83.58 | 94.42 | 97.54 |
Operating Margin | 9.17% | 18.25% | 19.81% | 9.36% | 15.82% | 15.39% | 16.43% | 16.41% |
Earnings before Tax (EBT) 1 | - | 15.91 | 7.62 | -263.9 | -121.1 | -19.04 | 13.67 | 62 |
Net income 1 | - | 4.383 | 19.38 | -158.7 | -156.2 | -0.5527 | 8.09 | 35.9 |
Net margin | - | 1.36% | 4.5% | -30.99% | -30.49% | -0.1% | 1.41% | 6.04% |
EPS 2 | - | 0.8900 | 0.4261 | -2.590 | -2.490 | -0.0807 | 0.0727 | 0.5535 |
Free Cash Flow 1 | - | 67.71 | 15.62 | -23.58 | - | 44.55 | 58.1 | 78 |
FCF margin | - | 21.08% | 3.63% | -4.6% | - | 8.2% | 10.11% | 13.12% |
FCF Conversion (EBITDA) | - | 93.46% | 19.34% | - | - | 46.2% | 55.9% | 70.91% |
FCF Conversion (Net income) | - | 1,544.74% | 80.62% | - | - | - | 718.15% | 217.29% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 10/6/20 | 3/25/21 | 3/10/22 | 3/31/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 130.4 | 117.3 | 140.3 | 137.1 | 125.8 | 119.1 | 137.1 | 120.8 | 135.4 | 129.5 | 137.6 | 131 | 145 | 138.7 | 146.8 |
EBITDA 1 | 28.49 | 7.111 | 22.93 | 22.66 | 15.23 | 16.95 | 28.16 | 21.74 | 22.02 | 22.62 | 25.36 | 20.95 | 27.36 | 23.85 | 27.71 |
EBIT 1 | 22.29 | 1.92 | 18.32 | 17.55 | 11.79 | 13.52 | 27.6 | 20.4 | 19.53 | 20.1 | 21.67 | 19.45 | 25.46 | 21.86 | 25.72 |
Operating Margin | 17.09% | 1.64% | 13.05% | 12.8% | 9.37% | 11.35% | 20.14% | 16.88% | 14.42% | 15.52% | 15.75% | 14.84% | 17.55% | 15.76% | 17.52% |
Earnings before Tax (EBT) 1 | -4.618 | -19.94 | -6.77 | 3.184 | -49.71 | -100.2 | -6.49 | -8.191 | -8.406 | -5.075 | -5.123 | -8.35 | -0.4805 | -4.153 | -0.1045 |
Net income 1 | - | -11.28 | - | - | - | -174.4 | -3.681 | -7.303 | -6.096 | -5.982 | -7.1 | -9.1 | -2.3 | -4.1 | -1.3 |
Net margin | - | -9.61% | - | - | - | -146.52% | -2.69% | -6.05% | -4.5% | -4.62% | -5.16% | -6.94% | -1.59% | -2.96% | -0.89% |
EPS 2 | -0.0100 | -0.1900 | -0.1100 | 0.0300 | -0.5200 | -2.240 | -0.0700 | -0.1200 | -0.1000 | -0.0700 | -0.0196 | -0.0607 | 0.0396 | -0.0600 | 0.005000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/10/22 | 5/10/22 | 8/11/22 | 11/8/22 | 3/31/23 | 5/16/23 | 8/8/23 | 11/7/23 | 3/12/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | 102 | 314 | 386 | - | 328 | 276 | 218 |
Net Cash position 1 | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | 1.402 x | 3.885 x | 5.825 x | - | 3.401 x | 2.655 x | 1.98 x |
Free Cash Flow 1 | - | 67.7 | 15.6 | -23.6 | - | 44.6 | 58.1 | 78 |
ROE (net income / shareholders' equity) | - | 26% | 22.3% | 1.9% | - | 7.67% | 12% | 14.1% |
ROA (Net income/ Total Assets) | - | 7.67% | 7.8% | 0.57% | - | 2.1% | 3.43% | 4.39% |
Assets 1 | - | 57.18 | 248.3 | -27,974 | - | -26.32 | 236.2 | 818.1 |
Book Value Per Share 2 | - | 2.500 | 6.090 | 4.070 | - | 3.450 | 3.740 | 4.180 |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 4.09 | 7.37 | 10 | - | 7.15 | 8 | 8 |
Capex / Sales | - | 1.27% | 1.71% | 1.96% | - | 1.32% | 1.39% | 1.35% |
Announcement Date | 10/6/20 | 3/25/21 | 3/10/22 | 3/31/23 | 3/12/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.77% | 413M | |
-25.24% | 7.29B | |
+8.49% | 6.75B | |
+15.10% | 5.5B | |
-18.37% | 4.75B | |
+14.96% | 4.1B | |
-20.73% | 3.93B | |
-28.50% | 2.7B | |
+43.74% | 2.31B | |
+1.98% | 2.06B |
- Stock Market
- Equities
- BVS Stock
- Financials Bioventus Inc.